Introduction
Neuroblastoma is one of the commonest and most lethal pediatric solid tumors and is believed to reflect aberrant differentiation of the developing sympathoadrenergic lineage of the neural crest [1, 2] . Neuroblastoma exhibits marked intratumoral and intertumoral heterogeneity, with high-risk tumors characterized by poor differentiation and chemoresistance [1, 2] . The current 5-year survival rate for patients with high-risk neuroblastoma is less than 50% despite aggressive and multimodal treatment [1] . Thus, this malignancy represents a significant unmet medical need, and the identification of new therapeutic agents is urgently needed.
Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is a master regulator of neural progenitor homeostasis, integrating multiple proliferation, and differentiation signals, and thus has been focused on as a potential target in neuroblastoma [3] . Previous studies showed that GSK-3β is a positive regulator of nuclear factor-κB (NF-κB)-mediated survival and chemoresistance of cancer cells [4] [5] [6] [7] [8] [9] [10] . Inhibition of the NF-κB signaling pathway has been shown to induce apoptosis in neuroblastoma cells [11, 12] . An increase of NF-κB transcriptional activity has been reported in neuroblastoma cells treated with doxorubicin or etoposide [13] . Previous reports have shown that tool compound, nonclinically applicable, GSK-3 inhibitors reduced the cell viability, by apoptosis induction, in a range of neuroblastoma cell lines, including those derived from clinically high-risk MYCN-amplified metastatic tumors, while not affecting the viability of differentiated neurons [14] [15] [16] [17] .
In the present study, we evaluated the antitumor effects of a clinical stage drug, 9-ING-41, a small-molecule inhibitor of GSK-3, in neuroblastoma cell lines and xenograft tumors. Previous studies have showed druglike properties of 9-ING-41, including good tolerability and antitumor activity in rodents [18] [19] [20] . Recent studies have shown that 9-ING-41 significantly enhanced the efficacy of chemotherapeutic drugs in glioblastoma and breast patient-derived xenograft (PDX) tumor models [21, 22] . Here, we demonstrate that GSK-3β expression is highly prevalent in human neuroblastomas and that the GSK-3 inhibitor 9-ING-41 is a potential therapeutic agent for the treatment of human neuroblastoma.
(Manassas, Virginia, USA). The GSK-3 inhibitor 9-ING-41 was provided by Actuate Therapeutics Inc. (Forth Worth, Texas, USA). SK-N-DZ cell line was established from metastatic poorly differentiated neuroblastoma with MYCN amplification, 11q deletion and TP53 mutation. SK-N-BE(2) cell line was established from a metastatic neuroblastoma with MYCN amplification and TP53 mutation. All other chemicals were obtained from Sigma (St. Louis, Missouri, USA).
Measurement of cell viability
Relative number of viable cancer cells was determined by measuring the optical density using CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] according to the manufacturer's instructions (Promega, Madison, Wisconsin, USA). A GI 50 value for each compound was calculated with a nonlinear regression model of standard slope using GraphPad Prism 6.0 software (GraphPad, La Jolla, California, USA).
Immunoblot analysis and antibodies
For immunoblots, cells were lysed as described previously [4] . Whole protein extract from cells was prepared as described [4] . Protein sample concentration was determined by Bradford protein assay, and equal amounts (30 μg) of protein were loaded in each well of SDS-polyacrylamide gel. Cell extracts were separated by 10% SDS-PAGE, transferred to polyvinylidene difluoride membrane, and probed as indicated. The following antibodies were used for immunoblot analysis: phosphoglycogen synthase, GAPDH, PARP, and X-linked inhibitor of apoptosis protein (XIAP) (Cell Signaling, Danver, Massachusetts, USA). Bound antibodies were detected as described previously [4] .
Xenograft tumor models
Athymic mice were housed under pathogen-free conditions in accordance with current regulations and standards of the National Institutes of Health. All animal research was approved by Northwestern University Institutional Animal Care and Use Committee. Female athymic nude mice (6-8 weeks old) were inoculated subcutaneously with 1 × 10 6 SK-N-BE(2) or SK-N-DZ neuroblastoma cells mixed with Matrigel (BD Biosciences; Billerica, Massachusetts, USA). Xenograft tumors were staged before initiating the treatment and mice were randomized into four treatment groups: control (DMSO), 9-ING-41, CPT-11, and CPT-11 + 9-ING-41. At the end of the study, subcutaneous xenograft tumors were fixed in 10% formalin and processed to paraffin embedding.
Immunohistochemical staining and TUNEL
Immunohistochemical staining was performed on paraffin sections of neuroblastoma tissue microarray assay and xenograft tumors. Paraffin sections were deparaffinized, and antigen retrieval was carried out in citric buffer in microwave for 10 min. The sections were incubated in 1% hydrogen peroxidase for 10 min to quench endogenous tissue peroxidase. Tissue sections were then incubated with the anti-GSK-3β antibody (Cell Signaling) overnight at + 4°C. The slides were stained using a standard EnVision + System-HRP kit (Dako, Carpinteria, California, USA) according to the manufacture's protocol. Immunohistochemical reactions were developed with diaminobenzidine as the chromogenic peroxidase substrate, and slides were counterstained with hematoxylin. Negative control samples included replacement of the primary antibody with nonimmune IgG1 (Dako). GSK-3β positive expression was defined as positive staining of more than 50% of cancer cells throughout the neuroblastoma tumor section.
TUNEL staining was performed according to manufacturer's protocol (ApopTag Detection Kit; EMD Millipore; Burlington, Massachusetts, USA). The percentage of apoptosis was calculated as the number of TUNEL-positive cells and bodies per 1000 cells counted in three randomly selected microscopic fields in each xenograft tumor sample.
Statistical analysis
Correlations between GSK-3β immunohistochemical staining of neuroblastoma tissue microarray assay and clinicopathological parameters were analyzed using Fisher's exact test. All other values are presented as mean SE. Cell viability assay and PDX tumor data were analyzed with one-way analysis of variance. P values less than 0.05 were considered significant. Statistical analysis was performed using GraphPad Prism 6.0 software (La Jolla, California, USA).
Results

GSK-3β expression in human neuroblastoma
Using immunohistochemical staining, we found that GSK-3β is highly expressed selectively in cancer cells in 67% of human neuroblastomas (34 of 51 cases) and in subcutaneous xenograft tumors established from SK-N-BE(2) and SK-N-DZ neuroblastoma cell lines (Fig. 1) . In human neuroblastoma, GSK-3β expression was not associated with clinical stage, survival or other clinicopathological parameters.
GSK-3 inhibitor 9-ING-41 decreases neuroblastoma cell viability and potentiates the antitumor effect of CPT-11 in vitro
Using neuroblastoma cell lines, we tested the effect of chemically distinct small-molecule inhibitors of GSK-3: AR-A014418, TDZD-8, and 9-ING-41 [18, 23, 24] . 9-ING-41 has been shown to be more selective for GSK-3 than for 320 other related kinases [20] . Because of the high homology of GSK-3 isoforms, all known competitive inhibitors of GSK-3β, including 9-ING-41, inhibit both GSK-3α and GSK-3β [18, 23, 25] . We found that all tested GSK-3 inhibitors suppressed the activity of GSK-3 in neuroblastoma cells as shown by downregulation of phospho-glycogen synthase, a direct downstream target of GSK-3 (Fig. 2a) . Moreover, expression of XIAP, an antiapoptotic protein regulated by NF-κB, was decreased in neuroblastoma cells treated with GSK-3 inhibitors (Fig. 2a) . Using a cell viability assay, we found that the GI 50 of GSK-3 inhibitor 9-ING-41 (50-100 nmol/l) for inhibiting the growth of SK-N-DZ and SK-N-BE(2) neuroblastoma cells was 10-60 times lower than the GI 50 of toolkit GSK-3 inhibitors, AR-A014418 and TDZD-8 (data not shown). Our results show that 9-ING-41 (0.1-1 μmol/l) inhibits GSK-3, as shown by downregulation of phosphoglycogen synthase expression, leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker (Fig. 2a and b) .
High-risk or relapsed neuroblastoma is resistant to most chemotherapeutic agents including CPT-11 [26] . A recently published study showed that 9-ING-41 potentiates the antitumor effects of the chemotherapeutic drug CPT-11 in models of breast cancer in vitro and in vivo [22] . We tested our hypothesis that inhibition of GSK-3 may overcome resistance to CPT-11 in neuroblastoma cells. Continuous treatment of cancer cell lines with the same concentration of drug for 72 h is not clinically relevant as tumor exposure decreases over time after drug administration owing to drug clearance. Therefore, we used pulses of drug exposure to neuroblastoma cells. Taking into account the plasma half-life of 9-ING-41 (~3 h) and CPT-11 (~8 h), we used the approach of clinically relevant pulsed in-vitro treatment (5 h) to mimic transient drug exposure in vivo. Using this approach, we tested different concentrations of 9-ING-41 (30-500 nmol/l) in combination with 0.5 μmol/l of CPT-11 (Fig. 2c) . The CPT-11 concentration of 0.5 μmol/l is based on its plasma C max = 0.5 μmol/l observed in pediatric patients when CPT-11 is administered intravenously at a dose of 60 mg/m 2 [26] . Neuroblastoma cells were treated with 9-ING-41, CPT-11, or CPT-11 + 9-ING-41 for 5 h (Fig. 2c) . After treatment, cells were washed, and all test compounds were replaced with fresh compoundfree cell culture media. Neuroblastoma cells were then allowed to continue growing for 72 h, and relative cell growth was measured by a cell viability assay. In SK-N-DZ neuroblastoma cells, we found that monotherapy (5 h) with 0.5 μmol/l 9-ING-41 (75% growth inhibition) 
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was more effective than treatment with CPT-11 (20% growth inhibition) at the same concentration (Fig. 2c) . In these studies, we found that 9-ING-41 potentiates the antitumor effects of 0.5 μmol/l CPT-11 when used at 120 nmol/l (P < 0.05) and 250 nmol/l (P < 0.05) (Fig. 2c) .
GSK-3 inhibitor 9-ING-41 potentiates the effects of CPT-11 in growth inhibition of neuroblastoma xenograft tumors
We used subcutaneous SK-N-BE(2) and SK-N-DZ xenograft tumor models to evaluate the antitumor effect of 9-ING-41 alone and in combination with CPT-11 ( Figs 3 and 4) . Before initiation of the treatment, SK-N-BE(2) and SK-N-DZ xenograft tumors were staged to~500 and 200 mm 3 , respectively. Animals were randomized to four treatment groups: control, 9-ING-41, CPT-11, and CPT-11 + 9-ING-41. Vehicle (DMSO) or drugs were injected intraperitoneally using the schedules indicated (Figs 3 and 4) . Our initial screening study showed that the growth of SK-N-BE(2) xenograft tumors was inhibited by 9-ING-41 or CPT-11 monotherapy, and 9-ING-41 + CPT-11 treatment led to SK-N-BE(2) tumor regression (Fig. 3) . Although we found that 9-ING-41 monotherapy did not significantly inhibit SK-N-DZ xenograft tumor growth, combined CPT-11 and 9-ING-41 therapy led to regression of SK-N-DZ tumors (Fig. 4) . Analysis of TUNEL staining revealed a significant increase in apoptosis in CPT-11 + 9-ING-41-treated SK-N-DZ xenograft tumors (P < 0.05) (Fig. 4c and d) .
Discussion
Arising from neural crest cells, neuroblastoma is an embryonal tumor accounting for~15% of childhood cancer deaths, with most high-risk neuroblastoma tumors being resistant to chemotherapy, surgery and radiation therapy [1] . There is thus an urgent need for new treatment approaches for this pediatric cancer population. Recently published study identified a specific activation of GSK-3 in neural crest cells as they depart from the neuroepithelium and become migratory mesenchymal cells [27] . GSK-3 activation is controlled by anaplastic lymphoma kinase, which is associated with poor prognosis in patients with neuroblastoma [27] . Examination of nine neuroblastoma cell lines revealed a clear correlation between activation of anaplastic lymphoma kinase and GSK-3 [27] . It has been demonstrated that genetic and pharmacological loss of GSK-3 activity leads to cytoskeletal changes in migratory neural crest cells as well as in neuroblastoma cells [27] . Recent studies have established GSK-3β, a positive regulator of NF-κB-mediated survival and chemoresistance of cancer cells [4] [5] [6] [7] [8] [9] [10] 21, 22] , as a potential therapeutic target in human neuroblastoma [14] [15] [16] [17] . Our data show that GSK-3β expression is highly prevalent in human neuroblastomas supporting a rationale for development of a GSK-3 targeted therapy. Although this study is the first to our knowledge to examine the expression of GSK-3β in human neuroblastomas, a number of other studies have demonstrated GSK-3β protein overexpression in human pancreatic, colon, ovarian, bladder, and breast carcinomas [5, 7, 9, 28, 29] .
In the present study, we tested a clinical stage GSK-3 smallmolecule inhibitor 9-ING-41, which shows profound antitumor activity in vitro and in vivo [18] [19] [20] [21] [22] . We demonstrate that inhibition of GSK-3 by 9-ING-41 decreases the survival of neuroblastoma cells in vitro, consistent with previously published studies targeting GSK-3 in neuroblastoma and other cancer types [4] [5] [6] [7] [8] [9] [10] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Previous studies have demonstrated that the inhibition of GSK-3 decreases cancer cell survival by suppression of the NF-κB-mediated expression of XIAP in different types of cancer [4, 6, 8, 22] . Here, we show that inhibition of GSK-3 by 9-ING-41 led to a decreased expression of XIAP and induction of apoptosis in neuroblastoma cells. These data are consistent with a prior report by Duffy et al. [16] who reported a novel GSK-3-mediated regulation of MYC (c-MYC and MYCN) mRNA levels in neuroblastoma. This group also reported that nonclinically applicable GSK-3 inhibitors induced large-scale cell death, by both p53-dependent and independent mechanisms, in neuroblastoma cells, primarily through activating apoptosis [16] .
Inhibition of GSK-3 has been shown as a promising approach to overcome chemoresistance of cancer cells and to potentiate chemotherapy [8, 21, 22, 30] . AR-A014418, a toolbox GSK-3 inhibitor, enhanced the anticancer effect of docetaxel and synergistically decreased the viability of renal cancer cells [8] . Similarly, AR-A014418 was shown to sensitize pancreatic cancer cells to gemcitabine [30] . Our previous work showed that 9-ING-41 potentiates antitumor effects of selected chemotherapeutic drugs in chemoresistant models of glioblastoma and breast cancer [21, 22] . Here, we found that inhibition of GSK-3 by 9-ING-41 sensitized neuroblastoma cells to CPT-11, a chemotherapeutic drug that has limited clinical activity in human neuroblastoma [26] . As continuous exposure (48-96 h) of neuroblastoma cells to either 9-ING-41 or a chemotherapeutic drug significantly suppresses cell viability and does not mimic tumor exposure to a drug in vivo, we used pulse treatments (5 h) of neuroblastoma cells using concentrations of 9-ING-41 in combination with CPT-11 based on the pharmacokinetics of each drug followed by washout with drug-free cell culture media and then allowed the cells to grow for 72 h. Under these conditions, we found that 9-ING-41 potentiated the antitumor effects of CPT-11 on neuroblastoma cell growth.
These in vitro results provided a rationale for further evaluation of 9-ING-41 in neuroblastoma xenograft models. We found that 9-ING-41 monotherapy inhibits the growth of SK-N-BE(2) xenograft tumors. Our findings are supported by another published study showing that treatment with toolkit GSK-3 inhibitor SB415286 suppressed the growth of xenograft tumors established from Neuro-2A neuroblastoma cell line [14] . Our previous in vivo studies showed a regression of breast cancer PDX tumors treated with combination of CPT-11 and 9-ING-41 [22] . Here, we found that treatment with the combination of CPT-11 and 9-ING-41 led to regression of established neuroblastoma xenograft tumors. These data are supported by our in vitro results showing that 9-ING-41 potentiates the antitumor effect of CPT-11 in neuroblastoma cells at clinically relevant concentrations after short-term exposure. Taken together, our findings provide a rationale for combining 9-ING-41 and CPT-11 as a potential novel therapeutic approach for the treatment of human neuroblastoma.
The Food and Drug Administration has granted 9-ING-41 orphan drug status for the treatment of neuroblastoma, and an investigational new drug application for 9-ING-41 has been recently approved by Food and Drug Administration for the first time in human phase I/II clinical trials. Our results suggest GSK-3β overexpression in neuroblastoma as a potential biomarker for the selection of patients in prospective 9-ING-41 clinical trials. Overall, the results of the current study provide a rationale for the advancement of 9-ING-41 into the clinic for the treatment of neuroblastoma.
